Novacyt
Research Novacyt (ALNOV) on Bullrun: market cap EUR 35.89M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALNOV
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryMedical Devices
- CurrencyEUR
- Market capEUR 35.89M
- Financial periodFY2025
- RevenueGBP 20.03M
- Revenue growth2.0%
- Net income-GBP 22.88M
- Free cash flow-GBP 9.89M
- Gross margin63.0%
Valuation Snapshot
latest market cap is EUR 35.89M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 20.03M | -GBP 22.88M | -GBP 9.89M | 63.0% | -0.32 | GBP 19.15M | GBP 10.45M | GBP 23.37M |
| FY2024 | GBP 19.63M | -GBP 41.76M | -GBP 11.01M | 163.4% | -0.59 | GBP 30.45M | GBP 11.88M | GBP 47.88M |
| FY2023 | GBP 10.62M | -GBP 28.29M | -GBP 23.05M | 32.9% | -0.4 | GBP 44.05M | GBP 13.70M | GBP 87.24M |
| FY2022 | GBP 21.04M | -GBP 25.73M | -GBP 14.15M | 27.3% | -0.36 | GBP 86.97M | GBP 872.00K | GBP 115.22M |
| FY2021 | GBP 92.60M | -GBP 9.73M | GBP 11.59M | 30.5% | -0.14 | GBP 101.75M | GBP 1.87M | GBP 141.82M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 35.89M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Novacyt's market cap?
Novacyt's market capitalization is EUR 35.89M.
What does Novacyt do?
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases.